TMEM97 and Alzheimer disease: The impacts of the putative σ1R-antagonist NE-100 and σ1R/σ2R-ligand rivastigmine on Aβ levels in a 3D neural model of AD describes a novel σ1R/σ2R-MAM axis in regulating amyloid pathology in AD (Bhattacharyya et al., 2021; Zellmer et al., 2024).